Key result
RGDC peptide improves neurological function and curbs neuroinflammation in ischemic stroke models via JAK-STAT.
Why the study?
Does the synthetic peptide Arg-Gly-Asp-Cys (RGDC) improve neurological function and reduce neuroinflammation in ischemic stroke models?
Does the synthetic peptide Arg-Gly-Asp-Cys (RGDC) improve neurological function and reduce neuroinflammation in ischemic stroke models?
Targeting the hypercoagulable state with RGDC improves outcomes in ischemic stroke models by modulating fibrin-driven microglial polarization.
Ischemic stroke is a leading cause of mortality and disability worldwide, yet its pathophysiological mechanisms remain poorly understood. In this study, we analyzed the coagulation function in 60 patients with acute ischemic stroke and found that their blood was in a hypercoagulable state. We confirmed this hematological change using a middle cerebral artery occlusion/reperfusion (MCAO/r) mouse model and improved the hypercoagulable state with the synthetic peptide Arg-Gly-Asp-Cys (RGDC), which inhibits platelet aggregation and fibrinogen binding. Interestingly, in MCAO/r mice, RGDC treatment led to enhanced neurological function, reduced blood-brain barrier (BBB) disruption, and alleviated neuroinflammation. Further analysis revealed that fibrin, the end product of coagulation, binds to ITGB2 on primary microglia and activates the JAK-STAT signaling pathway, influencing microglial polarization. These results establish a novel link between the hypercoagulable state and microglial function, offering a promising therapeutic approach to reduce neuroinflammation, improve neurological function and enhance outcomes in ischemic stroke by targeting coagulation pathways.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied acute ischemic stroke (n=60). Arg-Gly-Asp-Cys (RGDC) was evaluated on coagulation function, neurological function, blood-brain barrier disruption, and neuroinflammation. Patients with acute ischemic stroke exhibited hypercoagulability, and RGDC treatment in a mouse model enhanced neurological function and reduced neuroinflammation via the JAK-STAT pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: